Kinnate Biopharma Inc. (KNTE)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Nima Farzan
Employees:
27
11975 EL CAMINO REAL, STE 101, SAN DIEGO, CA 92130
8582994699

We are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.

Data derived from most recent annual or quarterly report
Market Cap 526.101 Million Shares Outstanding43.696 Million Avg 30-day Volume 240.091 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.49
Price to Revenue0.0 Debt to Equity0.0 EBITDA-97.464 Million
Price to Book Value1.6703 Operating Margin0.0 Enterprise Value195.73 Million
Current Ratio20.152 EPS Growth0.508 Quick Ratio17.521
1 Yr BETA 1.5333 52-week High/Low 26.05 / 7.18 Profit Margin0.0
Operating Cash Flow Growth-92.2147 Altman Z-Score15.9307 Free Cash Flow to Firm -71.105 Million
Earnings Report2022-08-15
View SEC Filings from KNTE instead.

View recent insider trading info

Funds Holding KNTE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KNTE BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-15:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-18:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MITCHELL DEAN J

    • Director
    20,250 2022-06-13 1

    GORDON CARL L

    • Director
    20,250 2022-06-13 2

    FLAHERTY KEITH T.

    • Director
    20,250 2022-06-13 1

    TANANBAUM JAMES B.

    • Director
    20,250 2022-06-13 1

    SMALDONE ALSUP LAURIE

    • Director
    20,250 2022-06-13 1

    SABZEVARI HELEN

    • Director
    20,250 2022-06-13 1

    EPPERLY MELISSA B,

    • Director
    20,250 2022-06-13 1

    ROME MICHAEL E

    • Director
    20,250 2022-06-13 1

    WILLIAMS RICHARD THOMAS CHIEF MEDICAL OFFICER

    • Officer
    42,333 2022-03-11 2

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED GENESIS GP LLC

    ORBIMED CAPITAL LLC

    • Director
    3,509,030 2022-02-11 1

    MELTZ MARK A COO GENERAL COUNSEL TREASURER

    • Officer
    135,000 2022-02-11 1

    FARZAN NIMA CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    400,000 2022-02-11 1

    KRISHNAMOHAN NEHA CHIEF FINANCIAL OFFICER

    • Officer
    185,000 2022-02-11 1

    MURPHY ERIC ANTHONY CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2021-02-12 0

    FORESITE CAPITAL MANAGEMENT IV, LLC

    FORESITE CAPITAL FUND IV, L.P.

    FORESITE CAPITAL MANAGEMENT V, LLC

    FORESITE CAPITAL FUND V, L.P.

    FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

    FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

    • 10% Owner
    10,838,311 2020-12-07 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED CAPITAL LLC

    750,000 2020-12-02 1

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VII LLC

    ORBIMED GENESIS GP LLC

    0 2020-12-02 1

    KALDOR STEPHEN W

    1,615,826 2020-12-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SABZEVARI HELEN - Director

    2022-06-15 17:01:14 -0400 2022-06-13 A 20,250 a 20,250 direct

    FLAHERTY KEITH T. - Director

    2022-06-15 17:01:07 -0400 2022-06-13 A 20,250 a 20,250 direct

    MITCHELL DEAN J - Director

    2022-06-15 17:00:44 -0400 2022-06-13 A 20,250 a 20,250 direct

    TANANBAUM JAMES B. - Director

    2022-06-15 17:00:43 -0400 2022-06-13 A 20,250 a 20,250 direct

    GORDON CARL L - Director

    2022-06-15 17:00:33 -0400 2022-06-13 A 20,250 a 20,250 direct

    ROME MICHAEL E - Director

    2022-06-15 17:00:29 -0400 2022-06-13 A 20,250 a 20,250 direct

    SMALDONE ALSUP LAURIE - Director

    2022-06-15 17:00:25 -0400 2022-06-13 A 20,250 a 20,250 direct

    EPPERLY MELISSA B, - Director

    2022-06-15 17:00:23 -0400 2022-06-13 A 20,250 a 20,250 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    KINNATE BIOPHARMA INC KNTE 2022-06-24 22:15:03 UTC 0.5248 1.0452 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 21:45:03 UTC 0.5248 1.0452 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 21:15:04 UTC 0.5248 1.0452 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 20:45:03 UTC 0.4484 1.1216 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 20:15:03 UTC 0.4484 1.1216 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 19:45:03 UTC 0.4484 1.1216 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 19:15:03 UTC 0.4484 1.1216 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 18:45:03 UTC 0.4778 1.0922 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 18:15:04 UTC 0.4778 1.0922 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 17:45:03 UTC 0.4778 1.0922 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 17:15:03 UTC 0.4778 1.0922 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 16:45:03 UTC 0.394 1.176 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 16:15:03 UTC 0.394 1.176 80000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 15:45:03 UTC 0.394 1.176 80000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 15:15:03 UTC 0.394 1.176 80000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 14:45:03 UTC 0.1599 1.4101 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 14:15:03 UTC 0.1599 1.4101 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 13:45:03 UTC 0.1599 1.4101 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 13:15:03 UTC 0.1599 1.4101 75000
    KINNATE BIOPHARMA INC KNTE 2022-06-24 12:45:03 UTC 0.1599 1.4101 75000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments